Nurix Therapeutics, Inc.
NRIXNASDAQHealthcare● Active
$15.64
+$1.00(+6.83%)
Market Cap$1.4B
P/E Ratio—
52W High$22.5
52W Low$8.195
Nurix Therapeutics, Inc. (NRIX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NRIX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 8, 2026EPS Actual
-$0.79
Est. -$0.76 · -4.0%
Revenue
$0.01B
Est. $0.01B · -56.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 8, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
NRIX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 9, 2026 | -$0.73 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | Apr 8, 2026 | -$0.76 | -$0.79 | -4.0% | $0.01B | $0.01B | -56.1% |
| ▲ Q1 FY2026 | Jan 28, 2026 | -$0.84 | -$0.82 | +2.4% | $0.01B | $0.01B | +1.3% |
| ▼ Q4 FY2025 | Oct 9, 2025 | -$0.84 | -$1.03 | -22.6% | $0.01B | $0.01B | -35.6% |
| ▲ Q3 FY2025 | Jul 9, 2025 | -$0.71 | -$0.52 | +26.8% | $0.04B | $0.02B | +151.6% |
| ▲ Q2 FY2025 | Apr 8, 2025 | -$0.72 | -$0.67 | +6.9% | $0.02B | $0.02B | +16.6% |
| ▼ Q1 FY2025 | Jan 28, 2025 | -$0.67 | -$0.75 | -11.9% | $0.01B | $0.01B | -10.1% |
| — Q4 FY2024 | Oct 11, 2024 | -$0.67 | -$0.67 | +0.0% | $0.01B | $0.01B | -1.7% |
Q3 FY2026
Jul 9, 2026
EPS Actual
—
EPS Est.
-$0.73
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 8, 2026Miss
EPS Actual
-$0.79
EPS Est.
-$0.76
EPS Surpr.
-4.0%
Revenue
$0.01B
Q1 FY2026
Jan 28, 2026Beat
EPS Actual
-$0.82
EPS Est.
-$0.84
EPS Surpr.
+2.4%
Revenue
$0.01B
Q4 FY2025
Oct 9, 2025Miss
EPS Actual
-$1.03
EPS Est.
-$0.84
EPS Surpr.
-22.6%
Revenue
$0.01B
Q3 FY2025
Jul 9, 2025Beat
EPS Actual
-$0.52
EPS Est.
-$0.71
EPS Surpr.
+26.8%
Revenue
$0.04B
Q2 FY2025
Apr 8, 2025Beat
EPS Actual
-$0.67
EPS Est.
-$0.72
EPS Surpr.
+6.9%
Revenue
$0.02B
Q1 FY2025
Jan 28, 2025Miss
EPS Actual
-$0.75
EPS Est.
-$0.67
EPS Surpr.
-11.9%
Revenue
$0.01B
Q4 FY2024
Oct 11, 2024
EPS Actual
-$0.67
EPS Est.
-$0.67
EPS Surpr.
+0.0%
Revenue
$0.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.22 | $-0.75 | $-0.18 | 7 |
| Q3 FY2027 | $-1.24 | $-0.76 | $-0.19 | 7 |
| Q2 FY2027 | $-1.20 | $-0.74 | $-0.18 | 7 |
| Q1 FY2027 | $-1.26 | $-0.78 | $-0.19 | 7 |
| Q4 FY2026 | $-1.19 | $-0.74 | $-0.18 | 7 |
| Q3 FY2026 | $-0.81 | $-0.74 | $-0.71 | 10 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 9 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 11 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 8, 2026 | -4.0% | $16.35 | $15.60 | -4.59% |
| ▲ Q1 FY2026 | Jan 28, 2026 | +2.4% | $19.41 | $17.87 | -7.93% |
| ▼ Q4 FY2025 | Oct 9, 2025 | -22.6% | $9.98 | $10.86 | +8.82% |
| ▲ Q3 FY2025 | Jul 9, 2025 | +26.8% | $12.21 | $13.18 | +7.94% |
| ▲ Q2 FY2025 | Apr 8, 2025 | +6.9% | $9.72 | $9.26 | -4.73% |
| ▼ Q1 FY2025 | Jan 28, 2025 | -11.9% | $19.81 | $19.56 | -1.26% |
| ▲ Q4 FY2024 | Oct 11, 2024 | +0.0% | $21.86 | $23.63 | +8.10% |
| ▼ Q3 FY2024 | Jul 11, 2024 | -7.6% | $20.24 | $22.03 | +8.84% |
Q2 FY2026-4.59%
Report Date
Apr 8, 2026
EPS Beat/Miss
-4.0%
Price Before
$16.35
Price After
$15.60
Q1 FY2026-7.93%
Report Date
Jan 28, 2026
EPS Beat/Miss
+2.4%
Price Before
$19.41
Price After
$17.87
Q4 FY2025+8.82%
Report Date
Oct 9, 2025
EPS Beat/Miss
-22.6%
Price Before
$9.98
Price After
$10.86
Q3 FY2025+7.94%
Report Date
Jul 9, 2025
EPS Beat/Miss
+26.8%
Price Before
$12.21
Price After
$13.18
Q2 FY2025-4.73%
Report Date
Apr 8, 2025
EPS Beat/Miss
+6.9%
Price Before
$9.72
Price After
$9.26
Q1 FY2025-1.26%
Report Date
Jan 28, 2025
EPS Beat/Miss
-11.9%
Price Before
$19.81
Price After
$19.56
Q4 FY2024+8.10%
Report Date
Oct 11, 2024
EPS Beat/Miss
+0.0%
Price Before
$21.86
Price After
$23.63
Q3 FY2024+8.84%
Report Date
Jul 11, 2024
EPS Beat/Miss
-7.6%
Price Before
$20.24
Price After
$22.03
Avg Beat Reaction+0.84%
Avg Miss Reaction+2.95%
Beat Rate4 / 8 quarters
Largest Move+8.84% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NRIX ends December
Nurix Therapeutics, Inc. (NRIX) most recently reported earnings on April 8, 2026 for Q2 FY2026, posting EPS of $-0.79 — missing the analyst consensus of $-0.76 by -4.0%. The next NRIX earnings date is expected around September 1, 2026.
Each quarter, investors track NRIX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NRIX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NRIX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NRIX earnings · 5 questionsNurix Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. NRIX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NRIX historically reports after market close (AMC).
NRIX earnings datewhen is NRIX earningsNRIX next earnings datewhen does NRIX report earningsNRIX earnings calendar
▸ Source: FMP · Nurix Therapeutics, Inc. SEC filings · US GAAP · Nurix Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026